Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood Samples…
SANTA ANA, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage…
SAN DIEGO and SUZHOU, China, March 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the…
Second clinical program entering Phase 2 with data expected 2026BRISBANE, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc.…
Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute Second Versamune® platform…
Company Achieves Key Clinical Milestone with more than 20 Patients Enrolled in Weekly Dosing Cohort of Phase 1 Trial of…
Olympus Will Highlight the Platform at Annual SAGES Meeting CENTER VALLEY, Pa., March 12, 2025 /PRNewswire/ -- Olympus Corp., a…
Astronauts to Support Cutting-Edge Biomedical Investigations, NSF-Funded Physical Science Projects, and More Through the ISS National Lab KENNEDY SPACE CENTER,…
Astronauts to Support Cutting-Edge Biomedical Investigations, NSF-Funded Physical Science Projects, and More Through the ISS National Lab KENNEDY SPACE CENTER,…
LOS ANGELES, March 12, 2025 /PRNewswire/ -- Salt AI, founded by the high-performance computing (HPC) team behind MySpace, today announces its…